Age: 65 Director since: 2017 Board and Committee Membership 2025 Attendance Board of Directors: 14/15 Audit Committee: 9/9 Compensation Committee: 8/8* Career Highlights Chair and CEO of TRATE Enterprises LLC, a privately held company, since 2013 Former Chair (from 2018 to 2024) and President and Chief Executive Officer (from 2019 to 2023) of Cerevel Therapeutics Holdings, Inc., the parent entity of Cerevel Therapeutics, Inc. Former Chief Executive Officer and Chair of the Board of Yumanity Therapeutics, Inc. Former President, Chief Executive Officer and Chair of the Board of Onyx Pharmaceuticals, Inc. Former President, Chief Executive Officer, and member of the board of directors of NPS Pharmaceuticals, Inc. Previously held various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol Myers Squibb Company, and Vertex Pharmaceuticals Incorporated Former director of Laboratory Corporation of America Holdings, Campus Crest Communities, Inc., CRISPR Therapeutics AG, and McKesson Corporation Experience and Expertise Industry Experience Executive/Leadership Experience Science/Biotech Background Research/Academic Experience Business Strategy/ Operations Experience Financial Expertise Public Company CEO Experience Dr. Coles was appointed as a member of the Compensation Committee of the board effective April 4, 2025. He attended all meetings of the Compensation Committee held after that date. Dr. Coles s experience as a seasoned executive and corporate director with extensive knowledge of highly regulated biopharmaceutical and pharmaceutical companies, as well as his in-depth knowledge and understanding of the regulatory environment in which Regeneron operates, led the board to conclude that Dr. Coles should serve as a director.